Abstract 381P
Background
The most frequent and aggressive primary brain malignancy in adults is a glioblastoma multiforme (GBM) which is frequently resistant to apoptosis-inducing chemotherapeutic agents. Surface exposure of phosphatidylserine (PS) is a universally recognized apoptotic phenomenon. Although in acute myeloid leukemia and T-cell lymphoma cells Xkr8 mediates PS exposure in response to apoptotic stimuli, the mechanisms underlying the regulation of Xkr8 expression remain unclear. Nevertheless, the loss of Xkr8 in blood cancer cells blocks cell-surface exposure of PS and causes dramatic decreasing of engulfment by phagocytes. Whether Xkr8 is dysregulated in specific cancers and contribute to the survival of patients has not been investigated. This study was aimed to investigate the association of overall survival (OS) and disease-free survival (DFS) with expression and copy number alterations (CNA) of XKR8 gene in GBM patients.
Methods
Data of gene expression, CNA and clinical information from 619 GBM tumors were obtained from TCGA Glioblastoma Multiforme study using the open platform CBioPortal. Among all cases, 572 GBM samples were with CNA (GISTIC 2.0. Values) data and 162 samples were with mRNA expression data (RNA Seq V2 RSEM). Patients were divided into two groups taking into account CNA or expression of mRNA. XKR8 expression was scored as downregulated when mRNA value was lower than the mean expression + standard deviation. XKR8 gene was marked as amplified when CNA value was equal 1 or 2. Kaplan-Meier and log-rank analyses were performed using RStudio.
Results
Survival analysis in GBM patients showed that the OS (p-value=0,015) of the group with downregulated XKR8 mRNA expression (n = 22) was better than of group with normal and upregulated expression (n = 140). Equivalent results have been shown for DFS, where the patients with low XKR8 expression (n = 15) had a weaker risk of disease recurrence (p-value=0,003) than other GBM patients (n = 103). Also, the OS of GBM patients with amplified XKR8 gene (n = 83) was worse (p-value=0,049) than of patients with other CNAs (n = 489).
Conclusions
Thus XKR8 gene can be characterized as prognostic biomarker of survival and disease progression in GBM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Research Laboratory "Biomarker" IFMB KFU.
Funding
Russian Government Program of Competitive Growth of Kazan Federal University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract